-
公开(公告)号:EP4442680A1
公开(公告)日:2024-10-09
申请号:EP22900244.9
申请日:2022-11-09
发明人: DENG, Haibing , YANG, Fei , ZHU, Wei , LIU, Xiaofeng , LIU, Jian , LI, Mingfeng , LIU, Zhaomin , YING, Haiyan , YU, Hongping , CHEN, Zhui , XU, Yaochang
IPC分类号: C07D237/32 , C07D401/14 , C07D401/04 , C07D471/14 , C07D471/04 , C07D487/04 , C07D498/04 , A61K31/502 , A61K31/517 , A61K31/519 , A61P35/00
CPC分类号: A61K31/502 , A61K31/517 , A61K31/519 , A61P35/00 , C07D237/32 , C07D401/04 , C07D401/14 , C07D471/04 , C07D471/14 , C07D487/04 , C07D498/04
摘要: A pyrazole derivative, and a preparation method therefor and a use thereof in medicine. In particular, the present invention relates to a PRMT5 inhibitor having a structure shown in formula (I), a preparation method therefor, a pharmaceutical composition containing same, a use thereof as a PRMT5 inhibitor, and a use thereof in treatment and/or prevention of a PRMT5-mediated disease.
-
公开(公告)号:EP3697767B1
公开(公告)日:2024-09-11
申请号:EP18868494.8
申请日:2018-10-16
IPC分类号: C07D311/02 , C07D311/04 , A61K31/282 , A61K31/4184 , A61K31/502 , A61K31/5025 , A61K31/545 , A61K31/704 , A61K31/7048 , A61K31/7052 , A61K33/24 , A61K45/06 , A61P35/00 , C07D405/14 , C07D407/12 , C07D309/10
CPC分类号: C07D405/14 , C07D309/10 , C07D311/02 , C07D311/04 , C07D407/12 , A61P35/00 , A61K31/7048 , A61K31/7052 , A61K31/704 , A61K45/06 , A61K31/282 , A61K33/24 , A61K31/502 , A61K31/4184 , A61K31/5025 , A61K31/545
-
公开(公告)号:EP3716976B1
公开(公告)日:2024-08-07
申请号:EP18926463.3
申请日:2018-11-14
IPC分类号: A61K31/4468 , C12N9/00 , A61K31/05 , A61K31/4178 , A61K31/44 , A61K31/4439 , A61K31/4545 , A61K31/47 , A61K31/502 , A61K31/506 , A61K31/519 , A61K31/675
CPC分类号: A61K31/496 , A61K31/495 , A61K31/4985 , A61K31/506 , A61K31/47 , A61K31/502 , A61K31/519 , A61K31/44 , A61K31/4178 , A61K31/4545 , A61K31/4439 , A61K31/675 , A61K31/05 , A61P25/24 , A61P35/04 , A61P35/02 , A61P9/00
-
公开(公告)号:EP4401721A1
公开(公告)日:2024-07-24
申请号:EP22881872.0
申请日:2022-10-17
申请人: University of South Alabama Foundation For Research and Commercialization , Canal House Biosciences, LLC
发明人: SOBOL, Robert, W. , GEORGE, Jay
IPC分类号: A61K31/145 , A61K31/7084 , A61P35/00
CPC分类号: A61P35/00 , A61K31/455 , A61K31/7084 , A61K31/706 , A61K31/502 , A61K31/55 , A61K31/5025 , A61K31/4184 , A61K31/454
-
公开(公告)号:EP4400117A1
公开(公告)日:2024-07-17
申请号:EP22867349.7
申请日:2022-09-06
申请人: Kyoto University
发明人: KONDOH Hiroshi , MIKAWA Takumi
IPC分类号: A61K45/00
CPC分类号: A61K31/08 , A61K31/138 , A61K31/166 , A61K31/352 , A61K31/366 , A61K31/407 , A61K31/409 , A61K31/4155 , A61K31/4178 , A61K31/4025 , A61K31/403 , A61K31/437 , A61K31/4188 , A61K31/4196 , A61K31/444 , A61K31/4375 , A61K31/438 , A61K31/4709 , A61K31/473 , A61K31/495 , A61K31/498 , A61K31/4985 , A61K31/502 , A61K31/505 , A61K31/506 , A61K31/53 , A61K31/519 , A61K31/52 , A61K31/7012 , A61K31/7028 , A61K31/7088 , A61K31/713 , A61K31/704 , A61K45/00 , A61P43/00 , C12Q1/02 , G01N33/15 , G01N33/52
摘要: The purpose of the present invention is to provide a screening method that enables efficient discovery of a novel senolytic drug and a senolytic drug obtained by the screening method. The present invention pertains to a senolytic drug that inhibits binding between PGAM and Chkl and also selectively kills senescent cells. More particularly, the senolytic drug of the present invention contains, as an active ingredient, at least one selected from the group consisting of an mRSK1 kinase inhibitor, an Fak kinase inhibitor, an inhibitor of signaling pathways involving Fak kinase, a CDK inhibitor, a calcium antagonist agent, an inotropic glycoside, a DNA damaging agent, an antimicrobial agent, an Aurora kinase inhibitor, a flavonoid, a PI3K kinase inhibitor, an HDAC inhibitor, a therapeutic agent for age-related macular degeneration, a p38 MAPK inhibitor, an mTOR inhibitor, a tyrosine kinase inhibitor, a Bcl-2 inhibitor, statin, a serotonin receptor antagonist, other kinase inhibitors and Nutlin-3b.
-
公开(公告)号:EP4398893A1
公开(公告)日:2024-07-17
申请号:EP22868132.6
申请日:2022-09-09
发明人: RAO, Srinivas, G. , SHORT, Glenn , BOWEN, Carrie , BUSBY, Robert
IPC分类号: A61K31/137 , A61K31/55 , A61K31/58 , A61P43/00
CPC分类号: A61K31/4706 , A61K31/4709 , A61K31/357 , A61K31/138 , A61K31/58 , A61K31/502 , A61K31/5415 , A61K31/5377 , A61K31/426 , A61K31/343 , A61K31/704 , A61K31/635 , A61K31/4525 , A61K31/454 , A61P25/30 , A61K31/166 , A61K31/55 , A61K31/137 , A61K31/506 , A61K31/4164 , A61K31/5513
-
公开(公告)号:EP4355364A1
公开(公告)日:2024-04-24
申请号:EP22825885.1
申请日:2022-06-17
发明人: THALER, Roman , VAN WIJNEN, Andre J. , LUCIEN-MATTEONI, Fabrice , DONG, Haidong , HUANG, Haojie , PARK, Sean S. , ORME, Jacob J.
CPC分类号: G01N30/72 , G01N2030/883120130101 , G01N30/88 , A61K31/502 , A61K31/55 , A61K31/454 , A61K31/5025 , A61K38/09 , A61K31/58 , A61K31/496 , A61K31/167 , A61K31/277 , A61K31/4166 , A61K31/4439 , A61K31/4155 , A61K31/517 , A61K31/5377 , A61K31/4709
-
8.
公开(公告)号:EP3406249A1
公开(公告)日:2018-11-28
申请号:EP18181342.9
申请日:2002-02-18
申请人: Novartis AG
IPC分类号: A61K31/436 , A61K45/06 , A61K31/4196 , A61K31/5685 , A61K31/451 , A61K31/366 , A61K31/58 , A61K31/4545 , A61P35/00
CPC分类号: A61K31/436 , A61K31/337 , A61K31/366 , A61K31/4196 , A61K31/439 , A61K31/451 , A61K31/4545 , A61K31/4745 , A61K31/475 , A61K31/502 , A61K31/555 , A61K31/5685 , A61K31/58 , A61K31/704 , A61K31/7068 , A61K33/24 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2300/00
摘要: 40-O-(2-hydroxyethyl)-rapamycin is used to treat hormone receptor positive breast tumors in combination with an aromatase inhibitor.
-
9.
公开(公告)号:EP2881395B1
公开(公告)日:2018-09-05
申请号:EP13825341.4
申请日:2013-07-24
申请人: Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai Acebright Pharmaceuticals Co., Ltd.
发明人: ZHANG, Ao , MIAO, Zehong , YE, Na , HUAN, Xiajuan , SONG, Zilan , CHEN, Chuanhuizi , CHEN, Yi , DING, Jian
IPC分类号: C07D487/04 , A61K31/4985 , A61K31/501 , A61K31/502 , A61P9/10 , A61P25/28 , A61P35/00
CPC分类号: C07D487/04 , A61K31/4985 , A61K31/501 , A61K31/502
摘要: Provided is a piperazinotriazole compound represented by general formula I or an isomer, a pharmaceutically acceptable salt, ester, prodrug or hydrate thereof. Also provided are a method for preparing the compound, a drug composition containing the compound, and a use thereof as a high-selectivity poly(ADP-ribose)polymerase-1 (PARP 1) inhibitor in the preparation of drugs for the prevention and / or treatment of PARP-related diseases.
-
公开(公告)号:EP3344286A1
公开(公告)日:2018-07-11
申请号:EP16843091.6
申请日:2016-09-02
IPC分类号: A61K39/00 , A61K31/337 , A61K31/704 , A61K45/06
CPC分类号: A61K31/337 , A61K31/138 , A61K31/4196 , A61K31/4745 , A61K31/4985 , A61K31/502 , A61K31/555 , A61K31/675 , A61K31/704 , A61K31/7048 , A61K31/7064 , A61K31/7068 , A61K33/24 , A61K39/0011 , A61K45/06 , A61K2039/575 , A61K2300/00
摘要: Provided herein are methods, kits and compositions for the treatment and/or prevention of ovarian cancer through the induction of an immune response against Anti-Mullerian Hormone Receptor, Type II (AMHR2).
-
-
-
-
-
-
-
-
-